Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Galapagos ( (GLPG) ) is now available.
Galapagos NV announced its financial results for the first nine months of 2025, revealing a strategic shift with the intention to wind down its cell therapy business. This decision follows a comprehensive strategic review aimed at optimizing capital allocation and supporting the company’s long-term sustainability. The wind down, if implemented, will affect approximately 365 employees and lead to the closure of several sites across Europe, the U.S., and China. Despite a significant operating loss of €462.2 million due to impairments, Galapagos maintains a robust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025. The company plans to focus on value-accretive transactions in small molecule and biologics programs, leveraging its partnership with Gilead to enhance its strategic positioning.
The most recent analyst rating on (GLPG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Galapagos stock, see the GLPG Stock Forecast page.
Spark’s Take on GLPG Stock
According to Spark, TipRanks’ AI Analyst, GLPG is a Neutral.
Galapagos faces significant financial challenges, with negative profitability and cash flow issues being the most impactful factors. The technical analysis suggests a bearish trend, with potential for a reversal. Valuation metrics are weak due to negative earnings and lack of dividends, further impacting the overall score.
To see Spark’s full report on GLPG stock, click here.
More about Galapagos
Galapagos NV is a biotechnology company based in Mechelen, Belgium, focusing on the discovery and development of small molecule and biologics programs, particularly in the fields of immunology and oncology. The company is known for its strategic partnership with Gilead Sciences, which provides exclusive access rights to Galapagos’ drug discovery platform.
Average Trading Volume: 220,478
Technical Sentiment Signal: Sell
Current Market Cap: $2.01B
For an in-depth examination of GLPG stock, go to TipRanks’ Overview page.